(“TCGFB”) to discover antibody therapeutics targeting Transforming Growth Factor Beta (TGF-ß) for the potential treatment of patients with idiopathic pulmonary fibrosis (IPF). Under the terms of the ...
In the early phase of Alzheimer’s disease, astrocytes are the primary source of APOE in the brain. This study examined the effects of astrocyte-derived human APOE isoforms in APOE-deficient mouse ...
(“TCGFB”) to discover antibody therapeutics targeting Transforming Growth Factor Beta (TGF-ß) for the potential treatment of patients with idiopathic pulmonary fibrosis (IPF).
Transforming growth factor-beta (TGF-β), a well-known morphogen, is recognized for its role in regulating growth and development. The study is published in the journal Nature Communications.
Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone ...
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
(“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders ...